Bioxcel Therapeutics Inc (BTAI)

$0.88 -0.01 (-0.83%)
Market Cap 27.40M
Revenue (ttm) 640,000.00
Net Income (ttm) -69.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,921.88%
Debt to Equity Ratio -0.95
Volume 461,700
Avg Vol 1,006,646
Day's Range N/A - N/A
Shares Out 30.88M
Stochastic %K 34%
Beta 0.27
Analysts Strong Sell
Price Target $14.60

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 475 238 6837
Address:
555 Long Wharf Drive, 12th Floor, New Haven, United States
Ozymandias_
Ozymandias_ Jul. 20 at 10:44 PM
$BTAI are they even allowed to do a public offering to pay their oaktree debt?
1 · Reply
WenABVEAudit
WenABVEAudit Jul. 20 at 4:11 PM
$BTAI no deal coming we are so fucked idk if I should sell now for a 6k loss or what
1 · Reply
MarkTheGenius
MarkTheGenius Jul. 20 at 2:54 PM
$BTAI $8 to .80 cents. Pitiful. Reverse Split time coming.
1 · Reply
CoffeeRocks
CoffeeRocks Jul. 20 at 12:27 PM
$CMND $AEMD $BTAI 2026 year of RS
0 · Reply
juanagustin2086
juanagustin2086 Jul. 18 at 7:27 PM
$BTAI
3 · Reply
AllAboutTheBread
AllAboutTheBread Jul. 17 at 5:44 PM
$BTAI how much time you got? november is likeliest time
0 · Reply
AllAboutTheBread
AllAboutTheBread Jul. 17 at 5:43 PM
$BTAI RIP to those bought in at 1.40 and above
1 · Reply
Dyliegoat
Dyliegoat Jul. 16 at 12:11 AM
$BTAI cmon baby! I need to off this car!
0 · Reply
WenABVEAudit
WenABVEAudit Jul. 15 at 9:36 PM
$BTAI tf you talking about
0 · Reply
AllAboutTheBread
AllAboutTheBread Jul. 15 at 7:20 PM
$BTAI peoples life saviings wiped out here in a few hours
0 · Reply
Latest News on BTAI
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

May 28, 2026, 7:00 AM EDT - 7 weeks ago

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)

2026-05-15T12:03:32.000Z - 2 months ago

BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

BioXcel Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Quarterly report: Q1 2026

BioXcel Therapeutics Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Earnings release: Q1 2026

BioXcel Therapeutics Transcript: Investor update

Apr 23, 2026, 2:00 PM EDT - 3 months ago

BioXcel Therapeutics Transcript: Investor update

BioXcel Therapeutics Slides: Investor update

Apr 23, 2026, 2:00 PM EDT - 3 months ago

BioXcel Therapeutics Slides: Investor update

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

Apr 17, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Apr 9, 2026, 7:53 PM EDT - 3 months ago

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

BioXcel Therapeutics enrolls first patients in BXCL501 trial

2026-04-08T11:09:11.000Z - 3 months ago

BioXcel Therapeutics enrolls first patients in BXCL501 trial

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

Apr 8, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright

2026-04-02T10:12:16.000Z - 3 months ago

BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright

BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA

2026-04-01T11:09:26.000Z - 3 months ago

BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

Apr 1, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)

2026-03-27T11:20:13.000Z - 4 months ago

BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

Mar 27, 2026, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

BioXcel Therapeutics Annual report: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Annual report: Q4 2025

BioXcel Therapeutics Earnings release: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Earnings release: Q4 2025

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Mar 11, 2026, 4:20 PM EDT - 4 months ago

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

Mar 10, 2026, 2:36 PM EDT - 4 months ago

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

BioXcel price target lowered to $6 from $10 at H.C. Wainwright

2026-03-05T13:59:23.000Z - 4 months ago

BioXcel price target lowered to $6 from $10 at H.C. Wainwright

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

2026-03-05T12:48:55.000Z - 4 months ago

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

2026-03-05T12:26:21.000Z - 4 months ago

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

Mar 5, 2026, 7:00 AM EST - 4 months ago

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

BioXcel Therapeutics Transcript: Status update

Feb 27, 2026, 2:00 PM EST - 5 months ago

BioXcel Therapeutics Transcript: Status update

BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia

2026-02-19T12:16:19.000Z - 5 months ago

BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia

Feb 19, 2026, 7:00 AM EST - 5 months ago

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia

BioXcel completes updated market opportunity assessment for Igalmi

2026-02-12T12:14:02.000Z - 5 months ago

BioXcel completes updated market opportunity assessment for Igalmi

BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi

2026-01-20T12:06:39.000Z - 6 months ago

BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting

Jan 20, 2026, 7:00 AM EST - 6 months ago

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Jan 15, 2026, 12:44 PM EST - 6 months ago

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

BioXcel Therapeutics appoints Pavao as acting CCO

2026-01-12T12:21:09.000Z - 6 months ago

BioXcel Therapeutics appoints Pavao as acting CCO

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

Jan 12, 2026, 7:00 AM EST - 6 months ago

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

BioXcel Therapeutics planning to submit sNDA seeking FDA approval for IGALMI

2026-01-07T12:05:31.000Z - 6 months ago

BioXcel Therapeutics planning to submit sNDA seeking FDA approval for IGALMI

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

Jan 7, 2026, 7:00 AM EST - 6 months ago

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

BioXcel Therapeutics Transcript: AGM 2025

Dec 12, 2025, 9:00 AM EST - 7 months ago

BioXcel Therapeutics Transcript: AGM 2025

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Dec 3, 2025, 7:00 AM EST - 8 months ago

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

BioXcel Therapeutics’ Igalmi supplement for new indication approved by FDA

2025-11-21T15:25:20.000Z - 8 months ago

BioXcel Therapeutics’ Igalmi supplement for new indication approved by FDA

BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)

2025-11-12T12:16:09.000Z - 8 months ago

BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

Nov 12, 2025, 7:00 AM EST - 8 months ago

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

BioXcel Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

BioXcel Therapeutics Quarterly report: Q3 2025

BioXcel Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

BioXcel Therapeutics Earnings release: Q3 2025

BioXcel Therapeutics Proxy statement: Proxy Filing

Nov 12, 2025, 7:00 AM EST - 8 months ago

BioXcel Therapeutics Proxy statement: Proxy Filing

BioXcel Therapeutics Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 9 months ago

BioXcel Therapeutics Proxy statement: Proxy Filing

BioXcel announces results from correlation study from SERENITY At-Home trial

2025-10-14T11:05:08.000Z - 9 months ago

BioXcel announces results from correlation study from SERENITY At-Home trial

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

Oct 14, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

Oct 13, 2025, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

BioXcel Therapeutics regains compliance with Nasdaq

2025-09-18T11:11:17.000Z - 10 months ago

BioXcel Therapeutics regains compliance with Nasdaq

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Sep 18, 2025, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

BioXcel Therapeutics Transcript: Study Result

Sep 10, 2025, 2:00 PM EDT - 11 months ago

BioXcel Therapeutics Transcript: Study Result

BioXcel Therapeutics Press release: Study Result

Sep 10, 2025, 2:00 PM EDT - 11 months ago

BioXcel Therapeutics Press release: Study Result

BioXcel Therapeutics Slides: Study Result

Sep 10, 2025, 2:00 PM EDT - 11 months ago

BioXcel Therapeutics Slides: Study Result

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 10, 2025, 6:30 AM EDT - 11 months ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:30 PM EDT - 11 months ago

BioXcel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 8:00 AM EDT - 11 months ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

BioXcel Therapeutics Transcript: Study Update

Aug 27, 2025, 8:00 AM EDT - 11 months ago

BioXcel Therapeutics Transcript: Study Update

BioXcel Therapeutics Press release: Study Update

Aug 27, 2025, 8:00 AM EDT - 11 months ago

BioXcel Therapeutics Press release: Study Update

BioXcel Therapeutics Slides: Study Update

Aug 27, 2025, 8:00 AM EDT - 11 months ago

BioXcel Therapeutics Slides: Study Update

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:29 AM EDT - 11 months ago

BioXcel's agitation drug meets main goal in at-home study

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 26, 2025, 4:00 PM EDT - 11 months ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 19, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Transcript: H.C. Wainwright & Co. “HCW@Home” Series 2025

Aug 14, 2025, 1:00 PM EDT - 1 year ago

BioXcel Therapeutics Transcript: H.C. Wainwright & Co. “HCW@Home” Series 2025

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 13, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

BioXcel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 12:00 PM EDT - 1 year ago

BioXcel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 12, 2025, 7:55 AM EDT - 1 year ago

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

BioXcel Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Quarterly report: Q2 2025

BioXcel Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q2 2025

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Aug 11, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 6, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 1, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Jul 21, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 1, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 1 year ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 27, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BioXcel Therapeutics Quarterly report: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Quarterly report: Q1 2025

BioXcel Therapeutics Earnings release: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q1 2025

BioXcel Therapeutics Annual report: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Annual report: Q4 2024

BioXcel Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q4 2024

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 27, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 11, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 4, 2025, 4:15 PM EST - 1 year ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 1 year ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Mar 3, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 28, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BioXcel Therapeutics Announces Reverse Stock Split

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split

BioXcel Therapeutics Registration statement: Registration Filing

Jan 10, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Registration statement: Registration Filing

BioXcel Therapeutics Proxy statement: Proxy Filing

Dec 30, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Proxy statement: Proxy Filing

BioXcel Therapeutics Proxy statement: Proxy Filing

Dec 18, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Proxy statement: Proxy Filing

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 22, 2024, 8:16 AM EST - 1 year ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

BioXcel Therapeutics Announces Proposed Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2024

BioXcel Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Quarterly report: Q3 2024

BioXcel Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings release: Q3 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference

Ozymandias_
Ozymandias_ Jul. 20 at 10:44 PM
$BTAI are they even allowed to do a public offering to pay their oaktree debt?
1 · Reply
WenABVEAudit
WenABVEAudit Jul. 20 at 4:11 PM
$BTAI no deal coming we are so fucked idk if I should sell now for a 6k loss or what
1 · Reply
MarkTheGenius
MarkTheGenius Jul. 20 at 2:54 PM
$BTAI $8 to .80 cents. Pitiful. Reverse Split time coming.
1 · Reply
CoffeeRocks
CoffeeRocks Jul. 20 at 12:27 PM
$CMND $AEMD $BTAI 2026 year of RS
0 · Reply
juanagustin2086
juanagustin2086 Jul. 18 at 7:27 PM
$BTAI
3 · Reply
AllAboutTheBread
AllAboutTheBread Jul. 17 at 5:44 PM
$BTAI how much time you got? november is likeliest time
0 · Reply
AllAboutTheBread
AllAboutTheBread Jul. 17 at 5:43 PM
$BTAI RIP to those bought in at 1.40 and above
1 · Reply
Dyliegoat
Dyliegoat Jul. 16 at 12:11 AM
$BTAI cmon baby! I need to off this car!
0 · Reply
WenABVEAudit
WenABVEAudit Jul. 15 at 9:36 PM
$BTAI tf you talking about
0 · Reply
AllAboutTheBread
AllAboutTheBread Jul. 15 at 7:20 PM
$BTAI peoples life saviings wiped out here in a few hours
0 · Reply
Paulbpaulb
Paulbpaulb Jul. 15 at 5:47 PM
$BTAI hurry up and wait
0 · Reply
bob397
bob397 Jul. 15 at 4:56 PM
$BTAI
0 · Reply
bob397
bob397 Jul. 15 at 4:45 PM
$BTAI Recent Key Developments Clinical Trials & Data: In late May 2026, BioXcel presented new clinical data from its SERENITY At-Home Phase 3 trial for IGALMI® (sublingual dexmedetomidine / BXCL501) at the ASCP Annual Meeting. The study is evaluating safety and efficacy for the acute treatment of agitation associated with bipolar disorders or schizophrenia in an at-home setting. US Department of Defense (DoD) Study: In April 2026, the company enrolled its first patients in a federally funded study investigating BXCL501's efficacy in treating acute stress reactions. Financial Position: For Q1 2026, BioXcel reported an EPS loss of -$0.54, which beat Wall Street consensus expectations of -$0.84 by over 35%. While the bottom-line performance beat estimates, the company reported no material revenue for the quarter as it continues to prioritize commercial expansion plans for IGALMI® in the at-home market.
1 · Reply
WenABVEAudit
WenABVEAudit Jul. 15 at 2:03 PM
$BTAI low volume drop today
2 · Reply
StockScanners
StockScanners Jul. 15 at 4:54 AM
$BTAI reached 1.17m lets go team be ready for next idea
0 · Reply
StockScanners
StockScanners Jul. 15 at 4:41 AM
$BTAI keep watch if this holds above .99
0 · Reply
TradeX_
TradeX_ Jul. 14 at 7:43 PM
Looks like BMGL might be the next 800% runner. Crazy market! Every micro float ticker has been going parabolic this month. Would not be surprised if they send BMGL up now. BMGL starting to make its move now! Only 750k shares outstanding! 💎 $BTAI $PDC $JBDI $IPST moving
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 14 at 4:52 PM
Trend $BWEN $GALT $ARBE $BTAI $ACTU
0 · Reply
topstockalerts
topstockalerts Jul. 14 at 4:46 PM
$BTAI this is holding way too well to ignore
0 · Reply
Oscarca
Oscarca Jul. 14 at 4:40 PM
$BTAI mad swings on this one
0 · Reply
CoffeeRocks
CoffeeRocks Jul. 14 at 4:39 PM
$APUS $BTAI $RGC $VEEE RGC 750$S then split Let’s see 80$ here
1 · Reply
prismmarketview
prismmarketview Jul. 14 at 4:38 PM
PRISM Mid-Day Movers: Fintech and Biotech are Today’s Leaders. AlphaTON Capital Corp. (NASDAQ: $ATON) is moving higher today, with the stock up about 23% to 0.2926 from a prior close of 0.2385. Actuate Therapeutics, Inc. (NASDAQ: $ACTU ) is having another strong session, with the stock up about 17% to 1.76 from a prior close of 1.50. Other Notable Movers: Galectin Therapeutics ( $GALT) up 18% BioXcel Therapeutics ( $BTAI) up 17% Mullen Automotive ( $MULN.X)down -19% https://prismmarketview.com/prism-mid-day-movers-fintech-and-biotech-are-todays-leaders/
0 · Reply